ICGi029-A-3

HCM14-3wt31

General

Cell Line

hPSCreg name ICGi029-A-3
Cite as:
ICGi029-A-3
Alternative name(s)
HCM14-3wt31
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 24th October 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG)
Owner Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG)
Distributors
Derivation country Russia

External Databases

BioSamples SAMEA116305377

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is affected.
Synonyms
  • Hypertrophic Cardiomyopathy

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA8307097

Ethics

Also have a look at the ethics information for the parental line ICGi029-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? sgRNA (GenScript), Cas9_NLS (NEB), and single-stranded donor oligonucleotides (Biolegio) were used for correction of the c.1543_1545delAAC (p.N515del) mutation in the MYBPC3 gene of patient-specific iPSCs (the ICGi029-A line)
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

The source cell information can be found in the parental cell line ICGi029-A.
Passage number reprogrammed 1

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Selection criteria for clones ESC-like morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Gelatin
Feeder cells Mouse embryonic fibroblasts
Passage method Enzymatically
TrypLE
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: Knock-out DMEM
Main protein source: Knock-out serum replacement
Serum concentration: 15 %
Supplements
NEAA 0.1 mM
GlutaMAX 1 mM
penicillin 100 U/ml
streptomycin 100 µg/ml
2-mercaptoethanol 0.05 mM
bFGF 10 ng/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SOX2
Yes
NANOG
Yes
SSEA-4
Yes
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
KRT18
Yes
Smooth Muscle Cell
Ont Id: CL_0000192
In vitro spontaneous differentiation
Marker Expressed
ACTA2
Yes
Neuron
Ont Id: CL_0000540
In vitro spontaneous differentiation
Marker Expressed
TUBB3
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: 8
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Synonyms
  • Hypertrophic Cardiomyopathy
Genetic modifications
MYBPC3 (target)
Isogenic modification
11p11.2
NM_000256.3:c.1543_1545delAAC
NP_000247.2:p.Asn515del
Heterozygous
A trinucleotide c.1543_1545delAAC (p.N515del) deletion was corrected in exon 17 of the MYBPC3 gene in patient-specific iPSCs (the ICGi029-A line) using CRISPR/Cas9 and single-stranded donor oligonucleotides
Repaired
Genetic modifications not related to a disease
MYBPC3 (target)
Isogenic modification
11p11.2
Heterozygous
Two synonymous substitutions were introduced in exon 17 of the MYBPC3 gene in patient-specific iPSCs (the ICGi029-A line) using CRISPR/Cas9 and single-stranded donor oligonucleotides to modify PAM and disrupt a restriction site for the BclI restriction endonuclease
Mutated